These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35662289)

  • 21. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency.
    Zanichelli A; Azin GM; Wu MA; Suffritti C; Maggioni L; Caccia S; Perego F; Vacchini R; Cicardi M
    J Allergy Clin Immunol Pract; 2017; 5(5):1307-1313. PubMed ID: 28284781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapies for hereditary angioedema: disease outlook changes dramatically.
    Frank MM; Jiang H
    J Allergy Clin Immunol; 2008 Jan; 121(1):272-80. PubMed ID: 18206518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
    Šimac DV; Štimac T; Novak S
    Curr Allergy Asthma Rep; 2022 Oct; 22(10):135-140. PubMed ID: 36044174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost.
    Rasmussen ER; Aagaard L; Bygum A
    Ann Allergy Asthma Immunol; 2016 May; 116(5):476-7. PubMed ID: 27017563
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study.
    Javaud N; Gompel A; Bouillet L; Boccon-Gibod I; Cantin D; Smaiti N; Carpentier F; Boubaya M; Launay D; Adnet F; Fain O
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):499-503. PubMed ID: 25935434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
    Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
    Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How satisfactory is on-demand icatibant from the patients' perspective in real life?
    Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
    Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
    [No Abstract]   [Full Text] [Related]  

  • 31. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
    Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
    J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
    [No Abstract]   [Full Text] [Related]  

  • 32. Current and emerging therapies to prevent hereditary angioedema attacks.
    Lumry WR
    Am J Manag Care; 2018 Aug; 24(14 Suppl):S299-S307. PubMed ID: 30132644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of acute attacks of hereditary angioedema: potential role of icatibant.
    Longhurst HJ
    Vasc Health Risk Manag; 2010 Sep; 6():795-802. PubMed ID: 20859548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Home treatment of hereditary angioedema with icatibant administered by health care professionals.
    Farkas H; Csuka D; Zotter Z; Varga L; Böröcz Z; Temesszentandrási G; Jakab L; Karádi I
    J Allergy Clin Immunol; 2012 Mar; 129(3):851-852.e2. PubMed ID: 22154383
    [No Abstract]   [Full Text] [Related]  

  • 35. Icatibant.
    Dubois EA; Cohen AF
    Br J Clin Pharmacol; 2010 May; 69(5):425-6. PubMed ID: 20573077
    [No Abstract]   [Full Text] [Related]  

  • 36. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
    Sabharwal G; Craig T
    Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical algorithm: Management of C1 inhibitor hereditary angioedema.
    Caballero T; Cabañas R; Pedrosa M
    Allergy; 2022 Mar; 77(3):1060-1063. PubMed ID: 34587298
    [No Abstract]   [Full Text] [Related]  

  • 38. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current management options for hereditary angioedema.
    Bork K
    Curr Allergy Asthma Rep; 2012 Aug; 12(4):273-80. PubMed ID: 22729959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinin formation in C1 inhibitor deficiency.
    Kaplan AP; Joseph K
    J Allergy Clin Immunol; 2010 Jun; 125(6):1411-2; author reply 1412. PubMed ID: 20381848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.